￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Oncology

LORVIQUA® receives positive opinion from CHMP as first-line treatment for ALK-positive advanced lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
US FDA approves Johnson & Johnson EGFR-MET bispecific antibody Rybrevant!

2025-10-19 11:44:20

Check Details
Can Rybrevant be purchased in Gansu? How much?

2025-10-19 11:44:20

Check Details
The lung cancer targeted drug dacomitinib significantly extends the survival time of advanced lung cancer!

2025-10-19 11:44:20

Check Details
Lumakras Approved in the United States to Treat KRAS-G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

2025-10-19 11:44:20

Check Details
The targeted drug Lumakras was approved to treat non-small cell lung cancer, with a control rate of 81%!

2025-10-19 11:44:20

Check Details
How effective is lorlatinib? How long does it take for Lorlatinib to take effect?

2025-10-19 11:44:20

Check Details
How long does it take for resistance to lorlatinib to develop? What are the side effects of lorlatinib?

2025-10-19 11:44:20

Check Details
HER3-targeted drug: FDA granted breakthrough therapy designation to Patritumab Deruxtecan for the treatment of EGFR+ NSCLC_ Kanghule

2025-10-19 11:44:20

Check Details
Known as the nemesis of BEGFR-20 insertion mutations, is bochitinib effective?

2025-10-19 11:44:20

Check Details
Tepotinib (Tepmetko) approved for marketing for the treatment of non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Tepotinib in the treatment of MET-positive NSCLC with meningeal metastasis _ Kanghule

2025-10-19 11:44:20

Check Details
Category
相关知识